Coloplast A/S (OTCMKTS:CLPBY) Stock Price Down 2.3% – What’s Next?

Posted by Teresa Graham on Dec 14th, 2024

Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) was down 2.3% during mid-day trading on Thursday . The stock traded as low as $11.49 and last traded at $11.49. Approximately 216,857 shares were traded during mid-day trading, an increase of 70% from the average daily volume of 127,904 shares. The stock had previously closed at $11.76.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on CLPBY shares. UBS Group raised Coloplast A/S from a “strong sell” rating to a “hold” rating in a research report on Wednesday. Hsbc Global Res upgraded Coloplast A/S from a “moderate sell” rating to a “hold” rating in a report on Monday, November 18th.

Get Our Latest Stock Analysis on CLPBY

Coloplast A/S Price Performance

The firm’s fifty day moving average price is $12.71 and its two-hundred day moving average price is $12.85. The company has a current ratio of 1.02, a quick ratio of 0.56 and a debt-to-equity ratio of 0.92.

Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported $0.08 earnings per share for the quarter. The business had revenue of $1.02 billion during the quarter. Coloplast A/S had a net margin of 18.69% and a return on equity of 30.19%. As a group, research analysts predict that Coloplast A/S will post 0.37 EPS for the current fiscal year.

Coloplast A/S Increases Dividend

The company also recently announced a dividend, which will be paid on Friday, December 20th. Shareholders of record on Monday, December 9th will be issued a $0.2435 dividend. This is an increase from Coloplast A/S’s previous dividend of $0.05. The ex-dividend date of this dividend is Monday, December 9th. Coloplast A/S’s dividend payout ratio is currently 96.97%.

About Coloplast A/S

(Get Free Report)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.